Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 173 of the 173 references it cites were found in a registry or an index.

Overcoming innate immune barriers that impede AAV gene therapy vectors

Open access
Muhuri, Manish, Maeda, Yukiko, Ma, Hong, Ram, Sanjay, Fitzgerald, Katherine A., Tai, Phillip W.L., Gao, Guangping · 2021 · Journal of Clinical Investigation

Abstract

The field of gene therapy has made considerable progress over the past several years. Adeno-associated virus (AAV) vectors have emerged as promising and attractive tools for in vivo gene therapy. Despite the recent clinical successes achieved with recombinant AAVs (rAAVs) for therapeutics, host immune responses against the vector and transgene product have been observed in numerous preclinical and clinical studies. These outcomes have hampered the advancement of AAV gene therapies, preventing them from becoming fully viable and safe medicines. The human immune system is multidimensional and complex. Both the innate and adaptive arms of the immune system seem to play a concerted role in the response against rAAVs. While most efforts have been focused on the role of adaptive immunity and developing ways to overcome it, the innate immune system has also been found to have a critical function. Innate immunity not only mediates the initial response to the vector, but also primes the adaptive immune system to launch a more deleterious attack against the foreign vector. This Review highlights what is known about innate immune responses against rAAVs and discusses potential strategies to circumvent these pathways.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci143780

Cites

173 of 173 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 172 references

Research works printed but not linked: 6

  1. Audentes therapeutics provides update on the ASPIRO clinical trial evaluating AT132 in patients with X-linked myotubular myopathy. Press release. Audentes Therapeutics. August 20, 2020. https://www.audentestx.com/press_release/audentes-therapeutics-provides-update-on-the-aspiro-clinical-trial-evaluating-at132-in-patients-with-x-linked-myotubular-myopathy/ Accessed November 2, 2020
  2. Pfizer’s new phase 1b results of gene therapy in ambulatory boys with duchenne muscular dystrophy (DMD) support advancement into pivotal phase 3 study. Press release. Pfizer. May 15, 2020. https://investors.pfizer.com/investor-news/press-release-details/2020/Pfizers-New-Phase-1b-Results-of-Gene-Therapy-in-Ambulatory-Boys-with-Duchenne-Muscular-Dystrophy-DMD-Support-Advancement-into-Pivotal-Phase-3-Study/default.aspx Accessed November 2, 2020
  3. Chan, 2019, Reducing AAV-mediated immune responses and pathology in a subretinal pig model by engineering the vector genome, Mol Ther, 27
  4. Letizia, 2019, Engineering AAV vectors to reduce CD8+ T cell responses following intramuscular injection in mice, Mol Ther, 27
  5. Pfizer presents initial clinical data on phase 1b gene therapy study for duchenne muscular dystrophy (DMD). Press release. Pfizer. June 28, 2019. https://www.pfizer.com/news/press-release/press-release-detail/pfizer_presents_initial_clinical_data_on_phase_1b_gene_therapy_study_for_duchenne_muscular_dystrophy_dmd Accessed November 2, 2020
  6. Solid Biosciences provides SGT-001 program update. Press release. Solid Biosciences. November 12, 2019. https://www.solidbio.com/about/media/press-releases/solid-biosciences-provides-sgt-001-program-update Accessed November 2, 2020

Cited by

See all 212

Metadata

Authors
Muhuri, M., Maeda, Y., Ma, H., Ram, S., Fitzgerald, K. A., Tai, P. W. L., & Gao, G.
Affiliations
University of Massachusetts Chan Medical School (US)
Venue
Journal of Clinical Investigation
Published
2021-01-04
Volume
131
Issue
1
ISSN
  • 0021-9738 (ISSN-L)
  • 1558-8238
OpenAlex
W3120585537
Cited by
212
References
172
Citations by year
2026: 39 · 2025: 45 · 2024: 59 · 2023: 30 · 2022: 28 · 2021: 11
FWCI
4.81
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • eScholarship@UMassChan (submittedVersion)
Funders
  • National Institutes of Health (AI067497)
  • National Heart, Lung, and Blood Institute (P01HL131471, R01HL097088, UG3HL147367)
  • National Institute of Allergy and Infectious Diseases (R01AI132296, R33AI136007, R01AI067497, R01AI128358, R37AI067497, P01AI100263, R01AI141181, U19AI149646, R56AI067497)
  • National Institute of Neurological Disorders and Stroke (R01NS076991)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
adeno-associated virus vectors, recombinant adeno-associated virus, innate immunity, immune evasion, gene therapy vectors, host immune response, in vivo gene therapy, immunogenicity
MeSH terms
Dependovirus, Animals, Genetic Vectors, Humans, Immunity, Innate, Genetic Therapy, Adaptive Immunity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Overcoming innate immune barriers that impede AAV gene therapy vectors. https://app.cochat.ai/papers/10.1172/jci143780
The paper
Muhuri, M., Maeda, Y., Ma, H., Ram, S., Fitzgerald, K. A., Tai, P. W. L., & Gao, G. (2021). Overcoming innate immune barriers that impede AAV gene therapy vectors. Journal of Clinical Investigation. https://doi.org/10.1172/jci143780

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.